1. Pink Sheet
  2. >>Geography
  3. >>Latin America

Countries Consider Pandemic Pooling of Rights And Compulsory Licensing

Transparency of R&D Costs Also Requested

 
• By Francesca Bruce

Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.

Coronavirus
Countries Consider How To Make COVID-19 Technologies Accessible

In an important move in the fight against the pandemic, Costa Rica has requested that the World Health Organization head an initiative to pool intellectual property rights relating to coronavirus technologies. Meanwhile Chile and Ecuador have paved the way for compulsory licenses, and the demand for more transparency on the costs of R&D and public financing is growing.

Costa Rica’s president, Carlos Alarado Quesada, and health minister Daniel Salas Peraza have written to the World Health Organization asking it to undertake a global initiative to pool rights to technologies developed to respond to the COVID-19 pandemic,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Latin America

Brazilian Drug Price Increase Rates Hit Eight-Year Low

 
• By Francesca Bruce

CMED, which sets medicine prices in Brazil, has published the maximum price adjustment index for 2025.

Brazil Catches Up With International Standards on Viral Safety Evaluations For Biotech Products

 
• By Francesca Bruce

The Brazilian medicines regulator will also offer more clarity on the requirements for radiopharmaceuticals that are exempt from registration.

Brazil Consults On How To Price Advanced Therapies

 
• By Francesca Bruce

Brazil’s drug regulator ANVISA has also published its first post-marketing authorization monitoring reports on advanced therapies Yescarta, Zolgenma, Kymriah, Carvykti and Luxturna.

England’s NICE Leads Global Effort On Surrogate Endpoints For Cost-Effectiveness

 
• By Eliza Slawther

Health technology assessment bodies in England, the US, Canada, Australia, the Netherlands and Colombia have joined forces to produce guidance for drug developers on using surrogate endpoints for cost-effectiveness analyses.

More from Geography

Trump Administration Push For Dismissal, Transfer Of Mifepristone Case Leaves Overhang For Pharma

 
• By Sarah Karlin-Smith

The Trump Administration requested a dismissal or transfer of a lawsuit seeking to tighten the safety requirements for the abortion pill mifepristone on procedural grounds, which still leaves the administration's position on the case's merits unclear.

Opioid Safety: US FDA Hears Mixed Messages On Adding Posmarketing Studies To Labeling

 
• By Sue Sutter

Some advisory committee members said adding quantitative data on misuse, abuse, opioid use disorder and overdose to labeling would be helpful, but others worried the two epidemiological studies were not sufficiently generalizable to a broader population.

Viatris Agrees To $335m Opioid Settlement Ending US State, Local Government Cases

 
• By Dean Rudge

Viatris joined Hikma and Amneal, in signing agreements for cash settlements that resolve allegations its practices fueled the US’ deadly opioid epidemic.